HomeCompareKNTE vs QSR

KNTE vs QSR: Dividend Comparison 2026

KNTE yields 75.47% · QSR yields 3.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KNTE wins by $1.33M in total portfolio value
10 years
KNTE
KNTE
● Live price
75.47%
Share price
$2.65
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.35M
Annual income
$375,142.22
Full KNTE calculator →
QSR
QSR
● Live price
3.40%
Share price
$73.90
Annual div
$2.51
5Y div CAGR
-0.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.7K
Annual income
$386.99
Full QSR calculator →

Portfolio growth — KNTE vs QSR

📍 KNTE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKNTEQSR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KNTE + QSR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KNTE pays
QSR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KNTE
Annual income on $10K today (after 15% tax)
$6,415.09/yr
After 10yr DRIP, annual income (after tax)
$318,870.89/yr
QSR
Annual income on $10K today (after 15% tax)
$288.70/yr
After 10yr DRIP, annual income (after tax)
$328.94/yr
At 15% tax rate, KNTE beats the other by $318,541.95/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KNTE + QSR for your $10,000?

KNTE: 50%QSR: 50%
100% QSR50/50100% KNTE
Portfolio after 10yr
$688.8K
Annual income
$187,764.60/yr
Blended yield
27.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on QSR right now

KNTE
Analyst Ratings
2
Buy
4
Hold
Consensus: Hold
Price Target
$30.00
+1032.1% upside vs current
Range: $30.00 — $30.00
Altman Z
1.0
Piotroski
2/9
QSR
Analyst Ratings
27
Buy
15
Hold
2
Sell
Consensus: Buy
Price Target
$81.57
+10.4% upside vs current
Range: $71.00 — $90.00
Altman Z
1.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KNTE buys
0
QSR buys
0
No recent congressional trades found for KNTE or QSR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKNTEQSR
Forward yield75.47%3.40%
Annual dividend / share$2.00$2.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-0.8%
Portfolio after 10y$1.35M$24.7K
Annual income after 10y$375,142.22$386.99
Total dividends collected$1.17M$3.7K
Payment frequencyquarterlyquarterly
SectorStockStock
Analyst consensusHoldBuy
Analyst price target$30.00$81.57

Year-by-year: KNTE vs QSR ($10,000, DRIP)

YearKNTE PortfolioKNTE Income/yrQSR PortfolioQSR Income/yrGap
1← crossover$18,247$7,547.17$11,037$336.93+$7.2KKNTE
2$32,395$12,870.51$12,154$344.76+$20.2KKNTE
3$56,017$21,354.74$13,357$351.99+$42.7KKNTE
4$94,449$34,510.84$14,651$358.62+$79.8KKNTE
5$155,442$54,381.15$16,041$364.68+$139.4KKNTE
6$249,967$83,643.80$17,534$370.18+$232.4KKNTE
7$393,173$125,708.24$19,136$375.14+$374.0KKNTE
8$605,486$184,791.09$20,856$379.58+$584.6KKNTE
9$913,831$265,960.98$22,699$383.52+$891.1KKNTE
10$1,352,941$375,142.22$24,675$386.99+$1.33MKNTE

KNTE vs QSR: Complete Analysis 2026

KNTEStock

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Full KNTE Calculator →

QSRStock

Restaurant Brands International Inc. operates as quick service restaurant company in Canada and internationally. It operates through four segments: Tim Hortons (TH), Burger King (BK), Popeyes Louisiana Kitchen (PLK), and Firehouse Subs (FHS). The company owns and franchises TH chain of donut/coffee/tea restaurants that offer blend coffee, tea, and espresso-based hot and cold specialty drinks; and fresh baked goods, including donuts, Timbits, bagels, muffins, cookies and pastries, grilled paninis, classic sandwiches, wraps, soups, and others. It is also involved in owning and franchising BK, a fast food hamburger restaurant chain, which offers flame-grilled hamburgers, chicken and other specialty sandwiches, french fries, soft drinks, and other food items; and PLK quick service restaurants that provide Louisiana style fried chicken, chicken tenders, fried shrimp and other seafood, red beans and rice, and other regional items. In addition, the company owns and franchises FHS restaurants quick service restaurants that offer subs, soft drinks, and local specialties. As of February 15, 2022, the company had approximately 29,000 restaurants in 100 countries under the Tim Hortons, Burger King, Popeyes, And Firehouse Subs brands. Restaurant Brands International Inc. was founded in 1954 and is headquartered in Toronto, Canada.

Full QSR Calculator →
📬

Get this KNTE vs QSR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KNTE vs SCHDKNTE vs JEPIKNTE vs OKNTE vs KOKNTE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.